Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2020-06-22 Earnings Release
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Press Release
Earnings Release Classification · 95% confidence The document is a press release from Morepen Laboratories Limited detailing the financial performance for the fiscal year 2019-20 and the fourth quarter of that fiscal year. It includes consolidated net profit, revenue, EBITDA, and segment-wise sales growth figures. The document also discusses new product launches, certifications, and business expansions. The presence of detailed financial data for both the annual and quarterly periods, including profit and loss figures, revenue breakdowns, and growth percentages, indicates this is a financial results announcement. However, it is not a full annual report (10-K) as it lacks comprehensive disclosures, notes, and management discussion typically found in such reports. It is also not a simple earnings release (ER) because it covers the full fiscal year and quarter with detailed financial metrics, but the format and content align closely with an Earnings Release. The document is not a report publication announcement (RPA) because it contains substantive financial data rather than just announcing the availability of a report. Therefore, the best classification is Earnings Release (ER).
2020-06-22 English
Appointment of Dr. Savita as a Non Executive, Independent Woman Director of the Company.
Interim / Quarterly Report Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) reporting the outcome of a Board of Directors meeting held on June 22, 2020. It includes approval of audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2020, which is a key indicator of a financial results announcement. It also mentions the report of auditors with an unmodified opinion, which is typically part of financial results disclosures. Additionally, the document reports other board decisions such as increase in authorized share capital (subject to member approval), adoption of new MOA and AOA, appointment of an additional independent director, and incorporation of subsidiaries. The document references compliance with SEBI regulations and circulars related to disclosure and publication of results. The length of the document (8633 characters) and the detailed content including financial results and auditor's report indicate this is not merely an announcement of a report but contains substantive financial data and board decisions. The primary focus is on the quarterly and annual financial results and related board approvals, which aligns with the definition of an Interim / Quarterly Report (IR). It is not a full Annual Report (10-K), nor just an announcement or certification. Therefore, the most appropriate classification is Interim / Quarterly Report (IR).
2020-06-22 English
Amendment to AOA/MOA
Board/Management Information Classification · 100% confidence The document text primarily discusses the appointment of a new director, Dr. Savita, including details such as the date of appointment, term, brief profile, and disclosure of relationships with other directors. There is no financial data, earnings information, or report content. The focus is on management changes, specifically a board appointment. The document length is short (1942 characters), and it is not an announcement of a report publication but a direct disclosure of a management change. Therefore, the appropriate classification is Board/Management Information (MANG).
2020-06-22 English
Increase in Authorised Capital
Board/Management Information Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) reporting the outcome of a Board of Directors meeting held on June 22, 2020. It includes approval of audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2020, along with the auditor's report. It also announces corporate actions such as increase in authorized share capital, adoption of new MOA and AOA, appointment of an additional independent director, and incorporation of subsidiaries. The document contains detailed disclosures about the new director's appointment and profile. The document is not the full annual report or financial statements but an official announcement of board decisions and financial results. It is not a certification or a short notice but a comprehensive board meeting outcome notice including financial results and corporate governance updates. Therefore, the document best fits the category of Board/Management Information (MANG) as it primarily announces board decisions including appointment of directors and approval of financial results, rather than being the full financial report itself or a simple earnings release.
2020-06-22 English
Appointment
Regulatory Filings Classification · 95% confidence The document is a formal communication addressed to stock exchanges (NSE and BSE) reporting the outcome of a Board of Directors meeting held on June 22, 2020. It includes several key points: approval of audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2020; increase in authorized share capital subject to member approval; adoption of new MOA and AOA subject to member approval; appointment of an additional independent director; and incorporation of two wholly owned subsidiaries. The document also encloses the auditor's report with an unmodified opinion and a declaration to that effect. The presence of audited financial results and auditor's report indicates this is a financial results announcement. However, the document is not the full annual report (10-K) but rather the official announcement of audited financial results and related board decisions. The document also includes management decisions and director appointment details. Given the focus on the audited financial results announcement and board meeting outcomes, this fits best under the category of Regulatory Filings (RNS) as it is a formal regulatory announcement of financial results and board decisions, not the full annual report or standalone audit report. The document length (8633 characters) and content support this classification rather than a brief announcement or a full report. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2020-06-22 English
Board of Directors of the Company, in their meeting held on Monday, 22nd June, 2020 (commenced at 12.00 Noon and concluded at 04.15 P.M.), have, inter-alia, considered and approved the ....
Annual Report Classification · 95% confidence The document is a detailed announcement from Morepen Laboratories Limited dated June 22, 2020, reporting the outcome of a Board of Directors meeting. It includes approval of audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2020, pursuant to SEBI regulations. The document contains the auditor's report with an unmodified opinion, detailed financial statements, management's responsibility statement, and auditor's responsibilities. The presence of comprehensive financial data, audit opinion, and detailed financial results for the full fiscal year indicates this is the official annual financial report. It is not merely an announcement or a certification but contains substantive financial data and analysis. Therefore, the document fits the definition of an Annual Report (10-K equivalent).
2020-06-22 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.